Related Experiment Video

Updated: Aug 8, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and

H Klein1, A Auricchio, S Reek

  • 1Division of Cardiology, University Hospital Magdeburg, Germany.

The American Journal of Cardiology
|March 25, 1999
PubMed

Insights

Preventing sudden arrhythmic death in heart failure patients is key. Two trials, SCD-Heft and MADIT II, investigate if implantable cardioverter defibrillators (ICDs) or amiodarone reduce total mortality in high-risk individuals.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Primary prevention of sudden arrhythmic death in patients with organic heart disease, poor left ventricular function, and heart failure remains a significant clinical challenge.
  • Amiodarone and implantable cardioverter defibrillators (ICDs) are primary therapeutic options for preventing sudden arrhythmic death in these high-risk patients.
  • Optimal heart failure and anti-ischemic treatments are crucial but may not eliminate the risk of sudden death in all patients.

Purpose of the Study:

  • To evaluate the prophylactic benefit of ICDs versus amiodarone on total mortality in patients with heart failure and reduced ejection fraction.
  • To compare the effectiveness of ICDs versus no ICD therapy in reducing total mortality in post-myocardial infarction patients with low ejection fraction.
  • To assess secondary endpoints including arrhythmic vs. non-arrhythmic mortality, morbidity, quality of life, and cost-effectiveness.

Main Methods:

  • The Sudden Cardiac Death in Heart Failure Trial (SCD-Heft) randomizes patients with heart failure (NYHA class II/III, LVEF < 35%) to amiodarone or ICD.
  • The Multicenter Automatic Defibrillator Implantation Trial (MADIT) II randomizes coronary artery disease patients (LVEF < 30%, post-MI) to ICD or no ICD.
  • Both trials utilize total mortality as the primary endpoint and include assessments of quality of life and cost-effectiveness.

Main Results:

  • The abstract does not contain specific results, but outlines the design and objectives of two major clinical trials.
  • These trials aim to define the role of ICDs and amiodarone in reducing mortality in specific high-risk heart failure populations.
  • Results from these studies are anticipated to guide clinical practice in the primary prevention of sudden arrhythmic death.

Conclusions:

  • The findings from SCD-Heft and MADIT II are expected to provide critical evidence for optimizing sudden arrhythmic death prevention strategies.
  • These trials will help determine the most effective therapeutic approach (ICD vs. amiodarone vs. optimal medical therapy) for high-risk heart failure patients.
  • The studies aim to improve survival rates and quality of life for patients susceptible to sudden cardiac death.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Concept Videos

Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...